Publication | Closed Access

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineHematologyImmunologyPharmacotherapy4-Year Follow-upImmunotherapyOncologyRadiation OncologyCancer ResearchHealth Sciences